Cargando…

SARS-CoV-2 infection induces protective immunity and limits transmission in Syrian hamsters

A critical question in understanding the immunity to SARS-COV-2 is whether recovered patients are protected against re-challenge and transmission upon second exposure. We developed a Syrian hamster model in which intranasal inoculation of just 100 TCID(50) virus caused viral pneumonia. Aged hamsters...

Descripción completa

Detalles Bibliográficos
Autores principales: Selvaraj, Prabhuanand, Lien, Christopher Z, Liu, Shufeng, Stauft, Charles B, Nunez, Ivette A, Hernandez, Mario, Nimako, Eric, Ortega, Mario A, Starost, Matthew F, Dennis, John U, Wang, Tony T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Life Science Alliance LLC 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893819/
https://www.ncbi.nlm.nih.gov/pubmed/33574037
http://dx.doi.org/10.26508/lsa.202000886
Descripción
Sumario:A critical question in understanding the immunity to SARS-COV-2 is whether recovered patients are protected against re-challenge and transmission upon second exposure. We developed a Syrian hamster model in which intranasal inoculation of just 100 TCID(50) virus caused viral pneumonia. Aged hamsters developed more severe disease and even succumbed to SARS-CoV-2 infection, representing the first lethal model using genetically unmodified laboratory animals. After initial viral clearance, the hamsters were re-challenged with 10(5) TCID(50) SARS-CoV-2 and displayed more than 4 log reduction in median viral loads in both nasal washes and lungs in comparison to primary infections. Most importantly, re-challenged hamsters were unable to transmit virus to naïve hamsters, and this was accompanied by the presence of neutralizing antibodies. Altogether, these results show that SARS-CoV-2 infection induces protective immunity that not only prevents re-exposure but also limits transmission in hamsters. These findings may help guide public health policies and vaccine development and aid evaluation of effective vaccines against SARS-CoV-2.